Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Production / Operations

Optimi Health Completes MDMA Export for PTSD Treatment Under Australia's Authorised Prescriber Scheme

By The Northwire Desk — AI Analysis Feb 09, 2026 · 07:01 OPTI · 0.34 Optimi Health Corp.
OPTI · Price

Executive Summary

  • Optimi Health Corp. completed its first export of 1,000 MDMA capsules (60 mg) to Australia under the Authorised Prescriber Scheme.
  • The shipment supports over 300 authorised PTSD treatment sessions and is part of a real‑world evidence study conducted by the Australian National University.
  • The export follows receipt of both Australian import permits and Health Canada export permits, confirming regulatory compliance for international distribution.

Key Details

  • Export Quantity: 1,000 MDMA capsules, each containing 60 mg of MDMA.
  • Therapeutic Use: Intended for authorised clinical programs treating Post‑Traumatic Stress Disorder (PTSD) via MDMA‑assisted therapy.
  • Treatment Capacity: Sufficient to support >300 PTSD treatment sessions under standard protocols.
  • Regulatory Approvals: Export authorized by Health Canada; Australian import permits obtained; Australian pharmacy partner acts as importer of record and national distributor.
  • Clinical Data Collection: Patient‑Reported Outcomes (PROs) are being gathered by the Australian National University to build a comprehensive real‑world evidence dataset on MDMA‑assisted therapy for PTSD.
  • Reimbursement Framework: The Australian Department of Veterans' Affairs offers reimbursement for eligible veterans receiving psychedelic‑assisted therapy under program requirements.
  • Market Context: Australian Bureau of Statistics estimates 5–6 % annual prevalence of PTSD (~1.3–1.5 million people), with higher rates among veterans and first responders.
  • Contact Information:
  • CEO Dane Stevens – (778) 761‑4551, [email protected]
  • Investor Relations – Lucas A. Zimmerman, MZ Group – (262) 357‑2918, [email protected]

Notable Quotes

(No direct quotes provided in the release.)

Read the original news release →

More from Optimi Health Corp.

Jun 29, 2026 · 09:00

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

Production / Operations Jun 16, 2026 · 08:30

Vertically integrated GMP psychedelic manufacturer scaling clinical supply, but revenue remains negligible and execution is incremental.

Production / Operations Jun 10, 2026 · 09:15

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

Production / Operations Jun 08, 2026 · 08:00

Psychedelic GMP manufacturer advances ibogaine development amid US policy tailwinds, but commercial revenue remains negligible.

Regulatory Jun 02, 2026 · 07:30

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

Production / Operations May 29, 2026 · 08:30

Australia widens insurance-backed psychedelic therapy access — Optimi’s existing supply chain gains yet another tailwind, but market still awaits proof-of-revenue.

Regulatory